Galaxy Biomedical Investment 

Galaxy Biomedical Investment Co., Ltd. operates in the transmission and distribution, electronic information, and bio-pharmaceutical industries in China. It operates through five segments: Power Transmission And Transformation, Electronic Components, Software, Biomedicine, and Others. The company offers rectifier, power, dry-type, distribution, and other small and medium-sized transformers for use in non-ferrous metal smelting, petrochemical, electrochemistry, new energy, and power grid companies; and displacement sensors, radio frequency components, resistors, and potentiometers. It also engages in the operation and maintenance, software sales, and network engineering activities; and agency product sales, and research and development services. In addition, the company engages in the research and development of drugs, such as immune cells, monoclonal antibodies, stem cells, and oncolytic viruses for the treatment of tumors. It also exports its products. The company was formerly known as Beihai Yinhe Industry Investment Co., Ltd. and changed its name to Galaxy Biomedical Investment Co., Ltd. in October 2015. Galaxy Biomedical Investment Co., Ltd. was founded in 1993 and is headquartered in Beihai, China.